Prevalence of Metabolic Syndrome and Risks of Abnormal Serum Alanine Aminotransferase in Hispanics: A Population-Based Study

Jen-Jung Pan1*, Hui-Qi Qu2, Anne Rentfro3, Joseph B. McCormick2, Susan P. Fisher-Hoch2, Michael B. Fallon1

1 Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America. 2 School of Public Health Brownsville Campus, University of Texas Health Science Center at Houston, Brownsville, Texas, United States of America, 3 College of Nursing, University of Texas at Brownsville, Brownsville, Texas, United States of America

Abstract

Aim: Study the prevalence of metabolic syndrome (MS) and risk factors for and association with elevated alanine aminotransferase (ALT) as markers of hepatic injury in a large Hispanic health disparity cohort with high rates of obesity.

Methods: Analysis of data from a prospective cross-sectional population-based study. From 2004-7, we randomly recruited 2000 community participants to the Cameron County Hispanic Cohort collecting extensive socioeconomic, clinical and laboratory data. We excluded 153 subjects due to critical missing data. Pearson chi-square tests and Student’s t-tests were used for categorical and continuous variable analysis, respectively. Logistic regression analysis was performed to determine the risk factors for elevated ALT.

Results: The mean age of the cohort was 45 years and 67% were females. The majority of the cohort was either overweight (32.4%) or obese (50.7%). Almost half (43.7%) had MS and nearly one-third diabetes. Elevated ALT level was more prevalent in males than females. Obesity was a strong risk for abnormal ALT in both genders. Hypertriglyceridemia, hypercholesterolemia and young age were risks for elevated ALT in males only, whereas increased fasting plasma glucose was associated with elevated ALT in females only.

Conclusion: We identified high prevalence of MS and markers of liver injury in this large Mexican American cohort with gender differences in prevalence and risk factors, with younger males at greatest risk.

Introduction

Minority populations including Hispanics suffer from severe health consequences of many preventable diseases, prominently obesity, diabetes and their complications. One of the complications of obesity is liver injury from nonalcoholic fatty liver disease (NAFLD) [1]. We have been recruiting and studying a community cohort of more than 2000 Mexican Americans living on the US/Mexico border for several years (the Cameron County Hispanic Cohort: CCHC) [2]. Among these health disparity participants, we have found extremely high rates of obesity (52%) and diabetes (20%). In an earlier chart review from a clinic serving the same, largely uninsured population we documented high frequency of chronic end-stage liver disease and hepatocellular carcinoma. Using ICD-9 discharge data codes for all forms of end-stage liver disease, we found rates of 126/100,000 overall rising to 136/100,000 in males [3]. Anecdotally gastroenterologists in the region reported that they see large number of patients with NAFLD, and the more severe consequence; nonalcoholic steatohepatitis (NASH). Accordingly we sought to obtain more precise prevalence data and better understanding of underlying risk factors as a first step to establishing burden of disease and developing interventions.

Most of the published prevalence information on NAFLD was derived from studies of Caucasian cohorts. According to a study based on the Third National Health and Nutrition Examination Survey (1988–1994), elevation of serum aminotransferases was more common in Mexican Americans than non-Hispanic whites [4]. The prevalence of NAFLD has been shown to be higher in Hispanic population than other ethnicities [5–7]. However, the number of Hispanics in these studies was relatively small, including two population-based reports [5,6]. In addition, selection bias is a risk in non-population-based studies.

Serum alanine aminotransferase (ALT) is frequently used as a surrogate marker for liver injury. The upper limit of the normal range varies in different laboratories according to the commercial
kit used and the reference population chosen. Nevertheless, the normal values have historically been set at around 40 units per liter (U/L) [6]. NAFLD is the commonest cause of abnormal liver enzymes in the developed world [1]. It is estimated that 20–30% of general population in Western countries and 10% in Japan have NAFLD [9,10]. The prevalence of NAFLD further increases to 91% in morbidly obese patients undergoing bariatric surgery [11] and 69.5% in patients with type 2 diabetes [12]. NAFLD is highly associated with such features of the metabolic syndrome (MS) as obesity, hypertension, dyslipidemia, and insulin resistance. It is even being considered as the liver manifestation of MS [1]. Among patients with NAFLD, 18% of normal-weight and 67% of obese subjects have MS [13].

To achieve our objectives we used weighted data from the CHCC cohort, to determine the prevalence of and risk factors for elevated ALT in this large Hispanic cohort. We focus especially on the known risks associated with MS.

Methods

Study population

From 2004 through 2007, we recruited 2000 participants to the CCHC [2]. These individuals were randomly selected based on the 2000 Census tract data in the city of Brownsville, Texas, one of the poorest Hispanic regions in US. Over 90% of the participants are Mexican Americans and over three quarters do not have health insurance of any kind [2]. A written consent was obtained from each participant. During the initial visit, participants were asked to complete a comprehensive questionnaire regarding their basic demographic information, medical history, medication use, and social and family history as described previously [2]. Blood samples were taken and aliquots immediately stored at −70°C for a range of clinical and experimental assays. Blood glucose and CBC were performed on site. Stored specimens were sent in batches to a CLIA approved clinical laboratory for clinical chemistries, including liver function tests. In our analyses we defined elevated ALT equal to or greater than 40 U/L. MS is defined based on the American Heart Association definition [14]. Briefly, MS is defined as the presence of at least three of the following: elevated waist circumference, ≥102 cm or 40 inches for men or ≥88 cm or 35 inches for women; elevated triglycerides≥150 mg/dl; reduced HDL cholesterol, <40 mg/dl for men or <50 mg/dl for women; elevated blood pressure≥130/85 mm Hg or use of medication for hypertension; and elevated fasting glucose≥100 mg/dl or use of medication for hyperglycemia. For assessment of Homeostasis Model Assessment Insulin Resistance (HOMA-IR), we measured fasting serum insulin levels.

This study has been approved by the Institutional Review Board of the University of Texas Health Science Center at Houston. We analyzed the demographic and laboratory data from each participant to determine the prevalence of and the risks associated with ALT elevation. After excluding 153 subjects due to missing liver enzyme or HOMA data, 1847 subjects were included in the final analysis.

Statistical analysis

Data are presented as means±SD for continuous variables and as frequencies for categorical variables. Comparisons between the two groups (ALT<40 vs. ALT≥40 U/L) were performed with Pearson chi-square tests for categorical variables, and Student’s t-tests for continuous variables. Univariate analysis with logistic regression was performed in order to determine the predictors of elevated ALT levels. Only those variables that had a statistically significant effect at the 0.05 level in the univariate analyses remained in the multivariate model. Unadjusted and adjusted odds ratios and 95% confidence intervals were presented. All reported p values were two-sided, and a p value of less than 0.05 was considered to indicate statistical significance. All statistical analyses were performed with SPSS 15.0 (SPSS Inc, Chicago, IL).

Results

Descriptive characteristics of the study cohort

As shown in Table 1, the mean age of the cohort subset we studied was 45 years. There were more females than males (67% vs. 33%, respectively). Overall, 83.1% of the study subjects were either overweight (32.4%) [body mass index (BMI) between 25 and 29.9] or obese (50.7%) [BMI≥30]. Nearly half (43.7%) have MS. Almost one-third have diabetes (American Diabetes Association 2010 definition) [15].

The cohort was further divided into 2 groups based on serum ALT levels as described. Elevated ALT level was more prevalent in males than females (figure 1). In addition, subjects with elevated ALT levels were younger (30–40 years), particular the males, were more obese, and were more likely to have features of MS especially

| Table 1. Descriptive characteristics of the study cohort based on serum ALT levels. |
|-----------------------------------|------------------|------------------|-------------------|
| Overall                          | ALT<40           | ALT≥40           |
| N = 1847                         | N = 1119         | N = 728          |
| Age (yr)                         |                  |                  |
| 45.0±15.2                       | 46.3±16.2        | 43.2±13.2        | <0.001            |
| Gender                           |                  |                  |
| Female                           |                  |                  |
| 1238 (67)                       | 861 (76.9)       | 377 (51.8)       |                  |
| Male                             |                  |                  |
| 609 (33)                        | 258 (23.1)       | 351 (48.2)       | <0.001            |
| BMI                              |                  |                  |
| <25                              |                  |                  |
| 312 (17)                        | 235 (21.2)       | 77 (10.5)        |                  |
| 25–29.9                         |                  |                  |
| 595 (32.4)                      | 387 (34.9)       | 208 (28.6)       |                  |
| ≥30                              |                  |                  |
| 931 (50.7)                      | 488 (44.0)       | 443 (60.9)       | <0.001            |
| ALT/AST ratio ≥1                |                  |                  |
| 1283 (69.5)                     | 684 (61.1)       | 599 (82.3)       | <0.001            |
| Metabolic syndrome              |                  |                  |
| 801 (43.7)                      | 442 (39.8)       | 359 (49.7)       | <0.001            |
| High blood pressure*            |                  |                  |
| 432 (23.4)                      | 249 (22.3)       | 183 (25.2)       | 0.15              |
| Waist circumference*            |                  |                  |
| 1258 (68.2)                     | 743 (66.6)       | 515 (70.7)       | 0.06              |
| Serum triglyceride≥150 mg/dL    |                  |                  |
| 795 (43.3)                      | 423 (37.9)       | 372 (51.5)       | <0.001            |
| Plasma glucose≥100 mg/dL        |                  |                  |
| 711 (38.5)                      | 385 (34.4)       | 326 (44.8)       | <0.001            |
| Low serum HDL                   |                  |                  |
| 927 (50.4)                      | 556 (49.8)       | 371 (51.2)       | 0.5               |
| Total cholesterol≥200 mg/dL     |                  |                  |
| 679 (36.8)                      | 375 (33.6)       | 304 (42.0)       | <0.001            |
| Diabetes                        |                  |                  |
| 508 (27.6)                      | 292 (26.2)       | 216 (29.8)       | 0.09              |
| Ever smoke                      |                  |                  |
| 547 (29.6)                      | 284 (25.4)       | 263 (36.1)       | <0.001            |
| Ever drink alcohol              |                  |                  |
| 912 (49.4)                      | 490 (43.8)       | 422 (58.0)       | <0.001            |
| Fasting serum insulin (μU/mL)   |                  |                  |
| 15.7±13.3                      | 13.4±9.4         | 19.2±17.2        | <0.001            |
| HOMA                             |                  |                  |
| 4.4±4.7                         | 3.6±3.0          | 5.5±6.3          | <0.001            |

Abbreviations: BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, high density lipoprotein; HOMA, homeostatic model assessment.

Note: Continuous variables are means±SD and categorical variables are numbers (%).

* Systolic pressure≥130 or diastolic pressure≥85 mm Hg.

**≥102 cm in males and ≥88 cm in females.

***≥40 mg/dl in males and <50 mg/dl in females.

*Either fasting plasma glucose≥126 mg/dl or HbA1C≥6.5 or already on treatment for diabetes.

doi:10.1371/journal.pone.0021515.t001
hypertriglyceridemia and increased fasting glucose levels. There was no significant difference in the prevalence of hypertension and low high-density lipoprotein (HDL) levels between the 2 groups. There was a trend for larger waist circumferences and more diabetes in the group with elevated ALT. More subjects who had elevated ALT had ever smoked or drank alcohol. Fasting serum insulin levels and HOMA values were higher in subjects with elevated ALT. The overwhelming majority (82.3%) of the subjects with elevated ALT had an ALT to aspartate aminotransferase (AST) ratio equal to or greater than 1, a feature usually seen in individuals with NAFLD [1] (table 1).

Gender differences among the study cohort

The prevalence of elevated ALT was higher in males than females (table 2 and figure 1). We therefore further characterized the gender differences. Age and the prevalence of diabetes were similar between genders. The female subjects were more obese and more likely to have MS. On the other hand, male subjects had higher total cholesterol levels and were more likely to have history of smoking and alcohol drinking than female subjects. When looking at the components of MS, female subjects were more likely to have central obesity and low HDL levels. Male subjects were likely to have elevated blood pressure, increased fasting triglyceride levels, and increased fasting glucose levels. There was no gender difference in fasting serum insulin levels or HOMA values. ALT/AST ratio equal to or greater than 1 was more prevalent in males than female counterparts.

Because of the existence of so many gender differences, it would not be reasonable to pool genders together for analysis. Overall, male gender had a 3-fold risk of developing elevated ALT levels compared to females. We therefore further dichotomized the cohort into 2 groups based on gender. During univariate analysis, obesity (BMI $\geq 30$), increased waist circumference and hypertriglyceridemia were significantly associated with elevated ALT in both genders. Aging [odds ratio (OR) 0.7, 95% confidence intervals (CI) 0.7–0.8], overweight (BMI 25–29.9) (OR 1.7, 95% CI 1.03–2.7) and hypercholesterolemia (OR 1.7, 95% CI 1.2–2.4) were significantly associated with elevated ALT in males only. On the other hand, the presence of MS (OR 1.9, 95% CI 1.5–2.4), hyperglycemia (OR 1.9, 95% CI 1.4–2.4), low serum HDL level (OR 1.4, 95% CI 1.1–1.8), and history of diabetes (OR 1.5, 95% CI 1.2–2.0) were significantly associated with elevated ALT in females only. Neither history of hypertension nor history of ever smoking or drinking alcohol predicted elevated ALT in both genders (table 3).

The results of multivariate analysis are shown in table 4. Aging was associated with lowering of ALT levels, especially in males (figure 1). Obesity was a strong risk for elevated ALT in both genders. There was a gender difference regarding the risk factors of abnormal ALT. Hypertriglyceridemia (OR 1.6, 95% CI 1.06–2.3) and hypercholesterolemia (OR 1.7, 95% CI 1.2–2.4) were again significant risk factors for males but not females. On the other hand, fasting glucose level greater than 100 mg/dl (OR 1.6, 95% CI 1.2–2.1) was a strong risk for abnormal ALT in females but not at all in males.

In this study, we found that younger males were especially at risk of having elevated ALT levels (figure 1). To find out the possible explanation, the male subjects were divided into three subgroups based on their age (age <35, N = 165; age 35–55, N = 206; age $\geq$56, N = 150). In multivariate analysis, obesity (BMI $\geq 30$; OR 7.0, 95% CI 2.4–20.2) was strongly associated with elevated ALT in males younger than but not old than 35 years. In addition, hypercholesterolemia (total cholesterol $\geq$200 mg/dl; OR 11.7, 95% CI 2.5–54.7) was also significantly associated with elevated ALT in males younger than 35 years but not in males aged between 35 and 55. Hypercholesterolemia, nevertheless, was moderately associated with elevated ALT in males older than 56 years (OR 2.7, 95% CI 1.3–5.6).
They are therefore at risk of developing complications of NAFLD, particularly in younger men [16]. In this study, we found that obesity and predictors of diabetes and cardiovascular disease, epidemic proportions as the younger males in this population age. Together these data show that Mexican Americans have a high risk of developing NASH and end-stage liver disease, consistent with our previous observations and the findings of the milder spectrums of NAFLD but may result in significant healthcare expenditure and questionable benefit. When applying the normal cutoffs proposed by Prati et al. [19] to the cohort of this study, we found that the majority of the participants would have abnormal ALT levels. Only 7 of 1238 female participants and only 68 of 609 male participants had ALT levels less than 19 U/L and 30 U/L, respectively. The findings argue that the normal ALT cutoffs for Hispanics may be different than that proposed for other ethnic populations [19].

The gender difference for the prevalence of elevated ALT in this study was remarkable. Male subjects had a 3-fold risk of having ALT level greater than 40 U/L as the normal cutoff value in this study. This value was historically based on population studies conducted before the availability of blood tests for hepatitis C and before the recognition of NAFLD [8]. The upper limit of the normal (ULN) range of ALT varies in different laboratories according to the commercial kit used and the reference population chosen. Age, gender, and BMI may be considered when determining the ULN for ALT [17,18]. A new ALT UNL for healthy males and females was proposed to be 30 U/L and 19 U/L, respectively [19]. It is conceivable that more people, especially women, with liver diseases may not be captured by using higher ALT levels as normal cutoffs. Nevertheless, Kunde and colleagues [20] reported that the new ALT standard proposed by Prati and colleagues [19] may be helpful for early recognition of the milder spectrums of NAFLD but may result in significant healthcare expenditure and questionable benefit. When applying the normal cutoffs proposed by Prati et al. [19] to the cohort of this study, we found that the majority of the participants would have abnormal ALT levels. Only 7 of 1238 female participants and only 68 of 609 male participants had ALT levels less than 19 U/L and 30 U/L, respectively. The findings argue that the normal ALT cutoffs for Hispanics may be different than that proposed for other ethnic populations [19].

The gender difference for the prevalence of elevated ALT in this study was remarkable. Male subjects had a 3-fold risk of having ALT level greater than 40 U/L as the normal cutoff value in this study. This value was historically based on population studies conducted before the availability of blood tests for hepatitis C and before the recognition of NAFLD [8]. The upper limit of the normal (ULN) range of ALT varies in different laboratories according to the commercial kit used and the reference population chosen. Age, gender, and BMI may be considered when determining the ULN for ALT [17,18]. A new ALT UNL for healthy males and females was proposed to be 30 U/L and 19 U/L, respectively [19]. It is conceivable that more people, especially women, with liver diseases may not be captured by using higher ALT levels as normal cutoffs. Nevertheless, Kunde and colleagues [20] reported that the new ALT standard proposed by Prati and colleagues [19] may be helpful for early recognition of the milder spectrums of NAFLD but may result in significant healthcare expenditure and questionable benefit. When applying the normal cutoffs proposed by Prati et al. [19] to the cohort of this study, we found that the majority of the participants would have abnormal ALT levels. Only 7 of 1238 female participants and only 68 of 609 male participants had ALT levels less than 19 U/L and 30 U/L, respectively. The findings argue that the normal ALT cutoffs for Hispanics may be different than that proposed for other ethnic populations [19].

The gender difference for the prevalence of elevated ALT in this study was remarkable. Male subjects had a 3-fold risk of having ALT level greater than 40 U/L as the normal cutoff value in this study. This value was historically based on population studies conducted before the availability of blood tests for hepatitis C and before the recognition of NAFLD [8]. The upper limit of the normal (ULN) range of ALT varies in different laboratories according to the commercial kit used and the reference population chosen. Age, gender, and BMI may be considered when determining the ULN for ALT [17,18]. A new ALT UNL for healthy males and females was proposed to be 30 U/L and 19 U/L, respectively [19].

The gender difference for the prevalence of elevated ALT in this study was remarkable. Male subjects had a 3-fold risk of having ALT level greater than 40 U/L as the normal cutoff value in this study. This value was historically based on population studies conducted before the availability of blood tests for hepatitis C and before the recognition of NAFLD [8]. The upper limit of the normal (ULN) range of ALT varies in different laboratories according to the commercial kit used and the reference population chosen. Age, gender, and BMI may be considered when determining the ULN for ALT [17,18]. A new ALT UNL for healthy males and females was proposed to be 30 U/L and 19 U/L, respectively [19].

The gender difference for the prevalence of elevated ALT in this study was remarkable. Male subjects had a 3-fold risk of having ALT level greater than 40 U/L as the normal cutoff value in this study. This value was historically based on population studies conducted before the availability of blood tests for hepatitis C and before the recognition of NAFLD [8]. The upper limit of the normal (ULN) range of ALT varies in different laboratories according to the commercial kit used and the reference population chosen. Age, gender, and BMI may be considered when determining the ULN for ALT [17,18]. A new ALT UNL for healthy males and females was proposed to be 30 U/L and 19 U/L, respectively [19].

The gender difference for the prevalence of elevated ALT in this study was remarkable. Male subjects had a 3-fold risk of having ALT level greater than 40 U/L as the normal cutoff value in this study. This value was historically based on population studies conducted before the availability of blood tests for hepatitis C and before the recognition of NAFLD [8]. The upper limit of the normal (ULN) range of ALT varies in different laboratories according to the commercial kit used and the reference population chosen. Age, gender, and BMI may be considered when determining the ULN for ALT [17,18]. A new ALT UNL for healthy males and females was proposed to be 30 U/L and 19 U/L, respectively [19].
Further studies are needed to clarify the underlying mechanism.

A major limitation of this study is that it was not specifically designed to study NAFLD, the diagnosis of which requires ruling out other liver diseases first. Nevertheless, the numbers are large and the data are impressive. This population-based study therefore provides an unbiased snapshot of the prevalence of and risks for abnormal liver tests in a large Hispanic cohort. Based on the National Health and Nutrition Examination Survey (NHANES), the prevalence rate of chronic hepatitis B and C infection in Mexican Americans was only 0.07% and 2.6%, respectively [23,24]. We previously had an opportunity to screen healthy Hispanic volunteers who lived in Brownsville, Texas for hepatitis B and C as pre-employment physicals previously. Among 320 people, none had hepatitis C and only one had hepatitis B infection (unpublished data). We therefore suspect the prevalence of viral hepatitis is likely low in our cohort. Another limitation is lack of detailed data regarding more than monthly alcohol consumption among the subjects. Such information was provided by the subjects voluntarily. However, the original questionnaire was not designed to scrutinize such data in finer detail. We cannot therefore exclude surreptitious alcohol use or other inaccuracies in reporting.

In conclusion, our report highlights a previously undocumented risk of end-stage liver disease in a health disparity population with significant gender differences. The excess representation among younger males is of particular concern. In this study, obesity (BMI ≥30) and hypercholesterolemia (total cholesterol ≥200 mg/dL) were significant predictors of elevated ALT. Multivariate analysis revealed that age, BMI, serum triglycerides, plasma glucose, and total cholesterol were independent predictors of elevated ALT.

**Table 3.** Univariate analysis of risk factors predicting elevated ALT based on gender.

|               | Female |               | Male |               |
|---------------|--------|---------------|------|---------------|
|               | N=1238 |               | N=609 |               |
| Age (by 10 yr increment) | 1.0 (0.9–1.04) | 0.7 (0.7–0.8) |
| BMI 25–29.9    | 1.5 (1.0–2.4) | 1.7 (1.03–2.7) |
| ≥30           | 3.2 (2.2–4.8) | <0.0001       | 3.0 (1.9–4.8) | <0.0001       |
| Metabolic syndrome | 1.9 (1.5–2.4) | <0.0001       | 1.4 (0.97–1.9) | 0.07          |
| High blood pressure<sup>a</sup> | 1.2 (0.9–1.7) | 0.1  | 0.9 (0.6–1.3) | 0.6           |
| Waist circumference<sup>b</sup> | 2.2 (1.6–3.0) | <0.0001       | 1.6 (1.1–2.2) | 0.006         |
| Serum triglyceride≥150 mg/dL | 1.5 (1.2–1.9) | 0.002       | 1.7 (1.3–2.4) | 0.0009        |
| Plasma glucose≥100 mg/dL | 1.9 (1.4–2.4) | <0.0001       | 1.0 (0.7–1.4) | 0.9           |
| Low serum HDL<sup>c</sup> | 1.4 (1.1–1.8) | 0.005       | 1.2 (0.8–1.7) | 0.3           |
| Total cholesterol≥200 mg/dL | 1.2 (0.9–1.6) | 0.2  | 1.7 (1.2–2.4) | 0.001         |
| Diabetes<sup>d</sup> | 1.5 (1.2–2.0) | 0.002       | 0.8 (0.6–1.2) | 0.3           |
| Ever smoke    | 1.3 (0.97–1.8) | 0.08       | 0.9 (0.7–1.3) | 0.5           |
| Ever drink alcohol | 1.2 (0.9–1.5) | 0.2  | 1.2 (0.8–1.7) | 0.4           |

Abbreviations: ALT, alanine aminotransferase; OR, odds ratio; CI, confidence interval; BMI, body mass index; HDL, high density lipoprotein.

<sup>a</sup>Systolic pressure≥130 or diastolic pressure≥85 mm Hg.
<sup>b</sup>≥102 cm in males and ≥88 cm in females.
<sup>c</sup><60 mg/dL in males and <50 mg/dL in females.
<sup>d</sup>Either fasting plasma glucose≥126 mg/dL or HbA1C≥6.5 or already on treatment for diabetes.

**Table 4.** Multivariate analysis of risk factors predicting elevated ALT based on gender.

|               | Female |               | Male |               |
|---------------|--------|---------------|------|---------------|
|               | N=1238 |               | N=609 |               |
| Age (by 10 yr increment) | 0.8 (0.8–0.9) | 0.0004       | 0.7 (0.6–0.8) | <0.0001       |
| BMI 25–29.9    | 1.5 (0.97–2.5) | 0.07       | 1.7 (0.99–2.8) | 0.05          |
| ≥30           | 2.9 (1.9–4.5) | <0.0001       | 2.7 (1.6–4.5) | 0.0002        |
| Serum triglyceride≥150 mg/dL | 1.3 (0.98–1.7) | 0.07       | 1.6 (1.06–2.3) | 0.02          |
| Plasma glucose≥100 mg/dL | 1.6 (1.2–2.1) | 0.0007       | 1.1 (0.8–1.6) | 0.6           |
| Total cholesterol≥200 mg/dL | 1.2 (0.91–1.6) | 0.08       | 1.7 (1.2–2.4) | 0.006         |

Abbreviations: ALT, alanine aminotransferase; OR, odds ratio; CI, confidence interval; BMI, body mass index.
References

1. de Alwis NM, Day CP (2008) Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 48(Suppl 1): S104–112.

2. Fisher-Hoch SP, Rentfro AR, Salinas JJ, Perez A, Brown HS, et al. (2010) Socioeconomic status and prevalence of obesity and diabetes in a Mexican American community, Cameron County, Texas, 2004-2007. Prev Chronic Dis 7: A53.

3. Perez A, Anzaldua M, McCormick J, Fisher-Hoch S (2004) High frequency of chronic end-stage liver disease and hepatocellular carcinoma in a Hispanic population. J Gastroenterol Hepatol 19: 209–205.

4. Clark JM, Brancati FL, Diehl AM (2003) The prevalence and etiology of nonalcoholic fatty liver disease. JAMA 290: 1023–1029.

5. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, et al. (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40: 397–403.

6. Weston SR, Leyden W, Murphy R, Bass NM, Bell BP, et al. (2005) Racial and ethnic distribution of nonalcoholic fatty liver disease in persons with newly diagnosed chronic liver disease. Hepatology 41: 372–379.

7. Kallwitz ER, Kumar M, Aggarwal R, Berger R, Layden-Almer J, et al. (2008) Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Dig Dis Sci 53: 1358–1365.

8. Dong MH, Bettencourt R, Barret-Coumar J, Loomba R (2010) Alanine aminotransferase decreases with age: the Rancho Bernardo Study. PLoS One 5:e14254.

9. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, et al. (2005) Prevalence of and risk factors for nonalcoholic fatty liver disease: the DiNausso nutrition and liver study. Hepatology 42: 44–52.

10. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, et al. (2005) Ethnicity and nonalcoholic fatty liver disease in obese women. Hepatology 42: 209–205.

11. Buchman A, Marques-Vidal P, Cortez-Pinto H (2006) Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 45: 600–606.

12. Targher G, Bertoli L, Padovani R, Rodella S, Tessari R, et al. (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30: 1212–1218.

13. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917–923.

14. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109: 433–438.

15. American Diabetes Association: Standards of medical care in diabetes-2010 (2010) Diabetes Care 33(Suppl 1): S11–S61.

16. Salinas J, McCormick JB, Rentfro A, Hans G, Hossain MM, et al. (2010) The missing men: high risk of disease in men of Mexican origin. Am J Mens Health 3: 1213–1219.

17. Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delatte J, et al. (1998) Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 27: 1213–1219.

18. Kariv R, Lehavi M, Beth-Or A, Strul H, Blendis L, et al. (2006) Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study. Liver Int 26: 445–450.

19. Prati D, Taïeli E, Zanella A, Della Torre E, Butelli S, et al. (2002) Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137: 1–10.

20. Kunde SS, Luuvenh AJ, Clemens RH, Abrams GA (2005) Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 42: 650–656.

21. Omagari K, Kadohawa Y, Masuda J, Egawa I, Sowa T, et al. (2002) Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 17: 1098–1105.

22. Miyazaki Y, Glass L, Triplitt C, Wajcberg E, Mandarino LJ, et al. (2002) Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Ann J Physiol Endocrinol Metab 283: E1135–1143.

23. Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, et al. (2010) Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study. Liver Int 26: 445–450.

24. Prati D, Taïeli E, Zanella A, Della Torre E, Butelli S, et al. (2002) Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137: 1–10.

25. Kunde SS, Luuvenh AJ, Clemens RH, Abrams GA (2005) Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 42: 650–656.

26. Omagari K, Kadohawa Y, Masuda J, Egawa I, Sowa T, et al. (2002) Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 17: 1098–1105.

27. Miyazaki Y, Glass L, Triplitt C, Wajcberg E, Mandarino LJ, et al. (2002) Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Ann J Physiol Endocrinol Metab 283: E1135–1143.